Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xyrem in Post-traumatic Narcolepsy and Hypersomnia
NCT03626727Phase 1Withdrawn
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sodium oxybate in narcolepsy and Hypersomnia (HS), sponsored by Brigham and Women's Hospital. Primary endpoint: Epworth Sleepiness Scale. Planned start Sep 2020; status: withdrawn.
02
Drugs
sodium oxybate
03
Conditions
narcolepsyHypersomnia (HS)
Beyond the preview
Go deeper on NCT03626727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03626727.